AlanP.VenookMD

Oncology • San Francisco, CA

Gastrointestinal Cancer, Hematologic Oncology

Professor of Medicine, UCSF

Join to view full profile

Dr. Venook is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Venook's full profile

Already have an account?

Office
1600 Divisadero St
San Francisco, CA 94143
Phone+1 415-353-9888

Fax+1 415-353-7150

Summary

Dr. Alan Venook is a nationally renowned expert in colorectal and liver cancers at the UCSF Helen Diller Family Comprehensive Cancer Center where he leads the Gastrointestinal Oncology program. In his research, he focuses on treating liver tumors with directed approaches, including infusional chemotherapy and biological agents.

Venook earned a medical degree at UCSF in 1980. He spent two years in the Public Health Service following an internship in internal medicine at UCSF. He completed a residence in internal medicine at the University of California, Davis and a fellowship in hematology and oncology at UCSF. Venook, who has been on the medical staff at UCSF since 1988, is a professor of medicine in hematology and oncology.

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1985 - 1988
University of California Davis HealthResidency, Internal Medicine, 1983 - 1985
University of California San Francisco School of MedicineClass of 1980

Certifications & Licensure

CA State Medical License 1981 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis Start of enrollment: 1998 Jun 01
Completed
Phase 1
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Start of enrollment: 2003 Dec 01
Terminated
Phase 3
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Celecoxib and Erlotinib in Treating Patients With Liver Cancer Start of enrollment: 2005 Jan 01
Withdrawn
Phase 1, Phase 2
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2009 Nov 17
Completed
Phase 1
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer Start of enrollment: 2011 Jun 01
Completed
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Start of enrollment: 2012 Jul 12
Completed
Phase 2
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2012 Oct 05
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Reply to: "Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy," "Large-Scale DPD Testing Should Be More Than an Option," and "A B...
Bani Tamraz, Alan P Venook
JCO Oncology Practice. 2024-12-03
Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity.
Kai R Trepka, Wesley A Kidder, Than S Kyaw, Taylor Halsey, Christine A Olson
Biorxiv. 2024-10-15
Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer.
En Cheng, Fang-Shu Ou, Clare Gatten, Chao Ma, Alan P Venook
Journal of the National Cancer Institute. 2024-08-30

Journal Articles

Association of Coffee Intake with Survival in Patients with Advanced or Metastatic Colorectal Cancer
I-Wen Chang, Charles D Blanke, Alan P Venook, Richard M Goldberg, Jeffrey A Meyerhardt, Kimmie Ng, JAMA Oncology
Identification of a Genomic Region Between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Hope S Rugo, Bryan P Schneider, Alan Venook, Clinical Cancer Research

Other

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Alan Venook, MD, The New England Journal of Medicine
https://www.doximity.com/articles/e0e95f3b-5b2a-480c-ab49-4608e3eb9632
UpToDate, Wolters Kluwer Health - 2013-03-12
Nonsurgical local treatment strategies for colorectal cancer liver metastases
Venook AP
http://www.uptodate.com/contents/nonsurgical-local-treatment-strategies-for-colorectal-cancer-liver-
UpToDate, Wolters Kluwer Health - 2012-09-28

Press Mentions

KRAS Inhibitors in Pancreatic Cancer: Hope on the Horizon?September 9th, 2024
Clinical Controversy: Watch-and-Wait or Surgery in Rectal Cancer near Complete Responders?August 20th, 2024
CRC in Middle Age Linked to Morning Sickness Pill from 60s, 70sMarch 19th, 2023
Join now to see all

Grant Support

Data Safety MonitoringNational Cancer Institute2007–2011
C98-118-01: Sch58500 &Chemotherapy In Colorectal Cancer Metastatic To LiverNational Center For Research Resources2000–2002
Core--Clinical Research Support ServicesNational Cancer Institute1999–2002
Cancer And Leukemia Group BNational Cancer Institute1995–2002